Document is current
Any future updates will be listed below
-
Authors
Townsend, Logan K. https://orcid.org/0000-0002-4311-2702
Wang, Dongdong https://orcid.org/0000-0002-6195-4428
Knuth, Carly M. https://orcid.org/0000-0002-7329-2476
Fayyazi, Russta
Mohammad, Ahmad
Becker, Léa J.
Tsakiridis, Evangelia E.
Desjardins, Eric M.
Patel, Zeel
Valvano, Celina M. https://orcid.org/0009-0008-5164-4224
Lu, Junfeng https://orcid.org/0000-0002-2640-8595
Payne, Alice E.
Itua, Ofure https://orcid.org/0009-0001-8999-136X
Medak, Kyle D.
Marko, Daniel M. https://orcid.org/0000-0001-6742-9731
Schertzer, Jonathan D. https://orcid.org/0000-0002-1547-5856
Wright, David C. https://orcid.org/0000-0003-3867-8901
Beaudette, Shawn M. https://orcid.org/0000-0002-8427-3959
Morrison, Katherine M. https://orcid.org/0000-0002-1737-256X
Carpentier, André C. https://orcid.org/0000-0002-3983-8156
Blondin, Denis P. https://orcid.org/0000-0001-6805-0985
MacPherson, Rebecca E. K. https://orcid.org/0000-0002-1577-2658
McCall, Jordan G. https://orcid.org/0000-0001-8295-0664
Jeschke, Marc G.
Steinberg, Gregory R. https://orcid.org/0000-0001-5425-8275
- License Information
-
More Information
Article History
Received: 27 August 2024
Accepted: 6 March 2025
First Online: 15 April 2025
Competing interests
: G.R.S. is a cofounder and shareholder of Espervita Therapeutics, a company developing new medications for fibrosis and cancer. McMaster University has received funding from Cambrian Biosciences, Catalym, Espervita Therapeutics, Esperion Therapeutics, Merck, Nestle, Novo Nordisk and Poxel Pharmaceuticals for research conducted in the laboratory of G.R.S. G.R.S. has received consulting and speaking fees from AstraZeneca, CurieBio, Eli Lilly, Esperion Therapeutics, Korro Bio, Keros Therapeutics, Merck, Novo Nordisk, Versant Ventures and Poxel Pharmaceuticals. A.C.C. received consulting and speaking fees from Eli Lilly, HLS Therapeutics, Janssen, Novartis Pharmaceuticals Canada and Novo Nordisk Canada. The other authors declare no competing interests.
